


BACKGROUND AND IMPORTANCE

Follicular B lymphoma (FL) is an indolent lymphoid neoplasm derived from germinal centre mutated B-cells with a nodular or follicular histological pattern. Approximately 2-3% of patients will transform their neoplasm to diffuse large B-cell lymphoma (DLBCL).

Epcoritamab-bysp (EPKINLY[®]) is a bispecific IgG1 antibody designed to simultaneously bind to CD3 on T cells and CD20 on B cells, and induces T cell-mediated killing of CD20+ cells.



OBJETIVE

The aim of this study is to evaluate the efficacy and safety of epcoritamab-bysp in a patient with LF refractory to previous lines

METHODS AND MATERIAL

Retrospective study of a clinical case in which we follow up a patient with R/R FL under treatment with epcoritamab-bysp.

Administration was done in the lower abdomen or thigh, and the injection was given at a different site each time it was administered. Data were obtained using the digitised clinical history (DIRAYA) and the electronic chemotherapy or immunotherapy prescription programme (ONCOFARM)

RESULTS

- **Patient:** ♀ 57 years old, 58,8 kg, 153 centimeters
- **Diagnosed in August 2020 with stage IV follicular B lymphoma without B symptoms.**
- **FL refractory different lines of treatment:** 1L: R-CHOP, 2L: R-ESHAP and a clinical trial with CAR-T therapy.

May 2023: Initiation of expanded use of epcoritamab-bysp monotherapy.

** In all immunotherapy sessions the patient was admitted for at least 24 hours due to risk of serious adverse reactions (cytokine release syndrome (CRS) or immunoeffector cell-associated neurotoxicity syndrome (ICANS)).*

- **In the second administration of epcoritamab-bysp the patient had a CRS grade 1** that resolved with the administration of intravenous dexamethasone 15 mg and intravenous paracetamol 1g.
- **From cycle 2 onwards, the target dose of immunotherapy was administered without incident.**
- **Using PET-CT, a partial metabolic response is observed with respect to the previous study.**

CONCLUSIONS

Despite the need for extended study time to evaluate the clinical Benefit and safety in real clinical practice of epcoritamab-bysp in patients with FL or DLBCL, this immunotherapy offers an innovative mechanism of action and an interesting alternative for patients with non-Hodgkin's lymphoma refractory to conventional therapies.